Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of VGR-R01 in Bietti Crystalline Dystrophy
NCT05399069Phase 1Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VGR-R01 in Bietti crystalline dystrophy (BCD), sponsored by Beijing Tongren Hospital. Primary endpoints: Incidence of adverse events at Day 365, Incidence of serious adverse events at Day 365 and 3 more. Status: unknown.
02
Drugs
VGR-R01
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on NCT05399069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399069.